Drug Profile
Rucosopasem manganese - Galera Therapeutics
Alternative Names: GC-4711; RucosopasemLatest Information Update: 02 Nov 2023
Price :
$50
*
At a glance
- Originator Galera Therapeutics
- Class Antifibrotics; Antineoplastics; Aza compounds; Cyclohexanes; Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Pancreatic cancer
- No development reported Unspecified
Most Recent Events
- 31 Oct 2023 Rucosopasem manganese receives Orphan Drug status for Pancreatic cancer in European Union before October 2023
- 31 Oct 2023 Galera Therapeutics halts a phase I/II GRECO-1 trial in Non small cell lung cancer (Early stage disease) in USA following futility analysis
- 31 Oct 2023 Galera Therapeutics halts a phase IIb GRECO-2 trial in Pancreatic cancer (Late stage disease) in USA following futility analysis